In the ever-evolving world of medical device manufacturing and life sciences, it’s crucial to have an exemplary team. That’s why we at Life Science Outsourcing, Inc. (“LSO”) are ecstatic to share the newest addition to our leadership team: Neil A. Goldman as our Chief Financial Officer (CFO).
Neil embodies the spirit of excellence and dedication that we uphold at LSO. Throughout his impressive career spanning three decades, Neil has scaled businesses through a keen understanding of financial, operational, commercial, and organizational dynamics. His tenure at Chembio Diagnostics, Inc. was marked by pivotal revenue growth, strategic shareholder engagement, and orchestrating international acquisitions. His roles at J.S. Held LLC and Unwired Technology LLC exemplify his prowess in driving sales growth, EBITDA performance, and closing and integrating acquisitions.
Neil started his career at Ernst & Young, where he started with a portfolio of Fortune 500 audit clients, and then advanced into regional and national consulting roles. When he left E&Y, Neil was responsible for High Growth/Middle Market Strategy Consulting between Boston and Chicago.
Neil is a proud alumnus of Miami University in Oxford, Ohio, where he earned a B.S. in Business-Accountancy.
John Nino, CEO, perfectly encapsulated our excitement, “With Neil on board, LSO is poised to fortify its position in the market. We eagerly anticipate the horizons and opportunities his leadership will unveil.”
As we usher in this new chapter with Neil A. Goldman, it’s essential to reiterate our core commitment at LSO. We are steadfast in our dedication to delivering unparalleled service to our clients.
About Life Science Outsourcing, Inc.
Life Science Outsourcing is an FDA-registered and ISO 13485-certified, performance-driven Contract Manufacturing Organization focused on assembly, packaging, sterilization, and specialized capabilities diagnostics packaging & design. Our unique business model emphasizes in-house, end-to-end processes and service offerings coupled with deep regulatory knowledge. This provides the agility and flexibility necessary to accelerate go-to-market launches while standardizing the supply chain and mitigating risk.
